Skip to content
PubMed This is a summary of 34 peer-reviewed journal articles Updated
Clinical Genetics · Immunodeficiency 107

Immunodeficiency 107 (IMD107) / OTULIN Haploinsufficiency: A Patient Guide

At a Glance

IMD107, or OTULIN haploinsufficiency, can leave skin and lung tissues vulnerable to rapidly destructive Staphylococcus aureus infections even when routine blood tests look normal. Genetic diagnosis and an emergency plan support rapid treatment with antibiotics and surgery.

Immunodeficiency 107 (IMD107), also known as OTULIN haploinsufficiency, is a recently discovered genetic condition that creates a hidden vulnerability in the body’s structural defenses. It is completely normal to feel overwhelmed when facing a newly identified and complex diagnosis, especially one that behaves differently from more common immune conditions. Unlike most immune disorders that involve a shortage of white blood cells or antibodies, IMD107 leaves the circulating immune cells largely unaffected but weakens the structural defenses of certain skin and lung cells. This means that while your routine blood work often appears unremarkable, your body lacks the necessary amount of OTULIN protein to protect your tissues from specific bacterial toxins, most notably those produced by Staphylococcus aureus (“Staph”) [1][2].

Emergency Action Information

Because routine blood tests can look normal during a life-threatening necrotizing event, you should keep an emergency action plan. Do not wait for a specialist if you experience rapidly spreading skin redness, pain out of proportion to a wound, or severe breathing difficulties; go to the emergency department immediately and present your genetic diagnosis and specialist contact information.

The hallmark of this condition is a susceptibility to invasive infections that can cause rapid necrosis, or tissue death. Because the defect is located in cells like dermal fibroblasts (skin cells) rather than the blood, a Staph infection that might be minor for someone else can quickly become a serious emergency for someone with IMD107. These episodes are often triggered by infections, physical trauma, or even surgical procedures, leading to severe pain and tissue damage that can spread across the skin or deep within the lungs [2][3].

Successfully managing IMD107 requires a specialized approach that looks beyond standard laboratory tests. Because routine immune panels often fail to detect the problem, a definitive diagnosis relies on detailed genetic testing to identify a single broken copy of the OTULIN gene, interpreted alongside your clinical history. Recognizing this “hidden” vulnerability is the first step toward building a proactive care plan that emphasizes rapid emergency response and a multidisciplinary team of experts [1][4].

When a crisis occurs, treatment must go beyond just clearing the bacteria. While antibiotics and surgical source control are essential to kill the infection and remove devitalized tissue, they may not immediately stop the ongoing tissue injury. In exceptionally rare cases where tissue necrosis progresses despite these measures, a multidisciplinary specialist team may carefully consider experimental, off-label immunomodulators—medications that calm the body’s inflammatory response. However, this is a rare possibility reported in isolated cases, not a standard protocol or escalation pathway, as suppressing the immune system can worsen an active infection. By combining expert medical oversight with a deep understanding of your body’s unique structural needs, you can navigate the challenges of IMD107 with a clear, individualized care plan [3][5].

Common questions in this guide

What is Immunodeficiency 107 (IMD107)?
IMD107 is a rare genetic condition also called OTULIN haploinsufficiency. A single nonworking copy of OTULIN can weaken protective functions in certain skin and lung cells, increasing the risk of rapidly destructive Staphylococcus aureus infections.
Can routine blood tests miss a serious infection in IMD107?
Yes. Because the main problem affects structural defenses in skin and lung cells while circulating immune cells may remain largely unaffected, routine immune tests can look normal even during a dangerous infection. A normal blood test should not delay emergency evaluation when warning signs are present.
Which symptoms require emergency care with IMD107?
Go to an emergency department immediately for rapidly spreading skin redness, pain that is much worse than expected for a wound, severe breathing difficulty, or sudden chest pain. Bring documentation of the genetic diagnosis and contact information for the treating specialists.
How is IMD107 diagnosed?
Diagnosis relies on genetic testing that identifies a single broken copy of the OTULIN gene and is interpreted alongside the person’s clinical history. Routine immune panels alone may not detect the condition.
How are severe Staph infections treated in IMD107?
Prompt antibiotics and surgical source control, including removal of devitalized tissue, are essential. Experimental off-label medicines that dampen inflammation have been considered only in exceptional cases under specialist supervision because suppressing immune responses can worsen an active infection.
How can I prepare for an IMD107 emergency?
Keep a medical alert document stating that normal routine blood tests do not rule out a severe infection, along with your genetic report and specialist contact information. Make sure you know which emergency symptoms require immediate care and who to call when they occur.

Get notified when new evidence is published on immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (5)
  1. 1

    Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin.

    Spaan AN, Neehus AL, Laplantine E, et al.

    Science (New York, N.Y.) 2022; (376(6599)):eabm6380 doi:10.1126/science.abm6380.

    PMID: 35587511
  2. 2

    Novel genotypes, phenotypes, and triggers in humans with OTULIN haploinsufficiency.

    van der Linden TJ, Arts RJW, Biggs CM, et al.

    Journal of human immunity 2025; (1(4)) doi:10.70962/jhi.20250018.

    PMID: 41293556
  3. 3

    Failure to Close: An Unexpected Surgical Complication Reveals OTULIN Haploinsufficiency.

    Nguyen J, Kim CF, Ramirez AA, Vogel TP

    ACR open rheumatology 2025; (7(3)):e11800 doi:10.1002/acr2.11800.

    PMID: 40084498
  4. 4

    Clinical exome sequencing of 1000 families with complex immune phenotypes: Toward comprehensive genomic evaluations.

    Similuk MN, Yan J, Ghosh R, et al.

    The Journal of allergy and clinical immunology 2022; (150(4)):947-954 doi:10.1016/j.jaci.2022.06.009.

    PMID: 35753512
  5. 5

    OTULIN Haploinsufficiency-Related Fasciitis and Skin Necrosis Treated by TNF Inhibition.

    Arts RJW, van der Linden TJ, van der Made CI, et al.

    Journal of clinical immunology 2023; (44(1)):10 doi:10.1007/s10875-023-01630-4.

    PMID: 38129331

This page explains IMD107 and OTULIN haploinsufficiency for educational purposes only and does not replace medical advice. Seek emergency care immediately for rapidly spreading skin changes, severe pain, or breathing difficulty, and discuss an individualized plan with your specialists.